PAP
ENTX icon

Persistent Asset Partners’s Entera Bio ENTX Stock Holding History

Persistent Asset Partners’s Portfolio ENTX Stock Details ENTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.4K Hold
5,881
– – ﹤0.01% 722
2026
Q1 		$6.53K Buy
+5,881
New +$8.25K ﹤0.01% 293

Other funds holding ENTX

KCM
Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $977M AUM 110.37% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return
SFCM
Seven Fleet Capital Management Mountain View, California $606M AUM
HighTower Advisors
HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

Persistent Asset Partners's ENTX Position: Q2 2026 in Review

Persistent Asset Partners held its Entera Bio (ENTX) position steady in Q2 2026 at 5,881 shares worth $10.4K. The position accounts for ﹤0.01% of the portfolio, ranked #722.

Persistent Asset Partners first reported a position in ENTX in Q1 2026 and has held it in 2 quarters since. 27 funds tracked by Wall St. Rank hold ENTX as of Q2 2026.

  • Persistent Asset Partners held 5,881 shares of Entera Bio worth $10.4K as of Q2 2026.
  • Persistent Asset Partners left its Entera Bio share count unchanged in Q2 2026.
  • Entera Bio made up ﹤0.01% of Persistent Asset Partners's portfolio in Q2 2026, its #722 holding.
  • Persistent Asset Partners first reported a position in Entera Bio in Q1 2026 and has held it in 2 quarters since.
  • 27 funds tracked by Wall St. Rank held Entera Bio as of Q2 2026.

Based on Persistent Asset Partners's 13F filing for Q2 2026, filed 7 Aug 2026.